Codexis, Inc.
CDXS Real Time Price USDRecent trades of CDXS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Lamar Smith House / R | Purchase $1,001 - $15,000 | Apr 06, 2018 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CDXS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Jan 18, 2013 Issue: Energy/Nuclear
-
$13,200 Oct 15, 2012 Issue: Chemicals/Chemical Industry
-
$5,244 Jul 19, 2012 Issue: Fuel/Gas/Oil Chemicals/Chemical Industry
-
$19,500 Apr 18, 2012 Issue: Science/Technology
-
$13,100 Oct 18, 2011 Issue: Fuel/Gas/Oil
-
$17,000 Jul 20, 2011 Issue: Fuel/Gas/Oil
-
$60,000 Jan 17, 2011 Issue: Energy/Nuclear
-
$60,000 Oct 19, 2010 Issue: Energy/Nuclear
-
$60,000 Jul 17, 2010 Issue: Energy/Nuclear
-
$60,000 Apr 18, 2010 Issue: Energy/Nuclear
-
$60,000 Jan 16, 2010 Issue: Energy/Nuclear
-
$80,000 Oct 19, 2009 Issue: Energy/Nuclear Environment/Superfund
-
$50,000 Jul 18, 2009 Issue: Energy/Nuclear Environment/Superfund
Estimated quarterly lobbying spending
CDXS Revenue by Segment or Geography
New patents grants
-
Patent Title: Engineered cyclic gmp-amp synthase (cgas) variant enzymes Dec. 31, 2024
-
Patent Title: Biocatalysts and methods for the synthesis of substituted lactams Dec. 10, 2024
-
Patent Title: Engineered dna polymerase variants Oct. 29, 2024
-
Patent Title: T7 rna polymerase variants Oct. 29, 2024
-
Patent Title: Engineered pantothenate kinase variant enzymes Oct. 08, 2024
-
Patent Title: Biocatalysts for ezetimibe synthesis Oct. 08, 2024
-
Patent Title: Engineered purine nucleoside phosphorylase variant enzymes Oct. 08, 2024
-
Patent Title: Penicillin-g acylases Sep. 10, 2024
-
Patent Title: Engineered amylase variants Aug. 27, 2024
-
Patent Title: Lov-d acyltransferase mediated acylation Aug. 13, 2024
-
Patent Title: Ketoreductase polypeptides for the production of azetidinone Jul. 30, 2024
-
Patent Title: Ketoreductase polypeptides for the preparation of phenylephrine Jul. 09, 2024
-
Patent Title: Engineered dna polymerase variants Jun. 25, 2024
-
Patent Title: Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine Jun. 18, 2024
-
Patent Title: Engineered galactose oxidase variant enzymes Jun. 18, 2024
-
Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds May. 21, 2024
-
Patent Title: Engineered acid alpha-glucosidase variants Apr. 30, 2024
-
Patent Title: Ketoreductase polypeptides for the production of (r)-3-hydroxythiolane Apr. 23, 2024
-
Patent Title: Penicillin-g acylases Apr. 23, 2024
-
Patent Title: Engineered protease variants Apr. 16, 2024
-
Patent Title: Variant lovd polypeptides and their uses Mar. 12, 2024
-
Patent Title: Engineered phenylalanine ammonia lyase polypeptides Feb. 27, 2024
-
Patent Title: Engineered adenylate kinase variant enzymes Feb. 27, 2024
-
Patent Title: Engineered acetate kinase variant enzymes Feb. 27, 2024
-
Patent Title: Engineered uridine phosphorylase variant enzymes Feb. 13, 2024
-
Patent Title: Engineered deoxyribose-phosphate aldolases Dec. 19, 2023
-
Patent Title: P450-bm3 variants with improved activity Nov. 07, 2023
-
Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Oct. 31, 2023
-
Patent Title: Engineered phosphopentomutase variant enzymes Oct. 24, 2023
-
Patent Title: Engineered transaminase polypeptides Oct. 17, 2023
-
Patent Title: Engineered amylase variants Sep. 26, 2023
-
Patent Title: Engineered glycosyltransferases and steviol glycoside glucosylation methods Sep. 19, 2023
-
Patent Title: Ketoreductase polypeptides and polynucleotides Sep. 05, 2023
-
Patent Title: Engineered biocatalysts and methods for synthesizing chiral amines Aug. 22, 2023
-
Patent Title: Treatment of gluten intolerance and related conditions Aug. 15, 2023
-
Patent Title: Compositions and methods for treating gluten intolerance and disorders arising therefrom Aug. 15, 2023
-
Patent Title: Biocatalysts for the preparation of hydroxy substituted carbamates Aug. 01, 2023
-
Patent Title: Compositions and methods for treating gluten intolerance and disorders arising therefrom Jul. 18, 2023
-
Patent Title: Penicillin-g acylases May. 09, 2023
-
Patent Title: Vectors for expression of biocatalysts Apr. 25, 2023
-
Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Apr. 04, 2023
-
Patent Title: Biocatalysts and methods for the synthesis of substituted lactams Mar. 07, 2023
-
Patent Title: Penicillin-g acylases Feb. 28, 2023
-
Patent Title: P450-bm3 variants with improved activity Feb. 28, 2023
-
Patent Title: Biocatalysts and methods for hydroxylation of chemical compounds Jan. 10, 2023
-
Patent Title: Transaminase polypeptides Jan. 03, 2023
-
Patent Title: Automated screening of enzyme variants Dec. 27, 2022
-
Patent Title: Engineered ketoreductase polypeptides Nov. 29, 2022
-
Patent Title: Human alpha-galactosidase variants Nov. 15, 2022
-
Patent Title: Ketoreductase polypeptides for the reduction of acetophenones Oct. 25, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CDXS
Recent picks made for CDXS stock on CNBC
ETFs with the largest estimated holdings in CDXS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CDXS stock a Buy, Sell, or Hold?
- What is the price target for $CDXS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CDXS stock?
- Who owns the most shares of $CDXS stock?
- What funds own $CDXS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CDXS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.